tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Shea, 9 are a BUY (100%).
Analyst Matthew Shea, currently employed at NEEDHAM, carries an average stock price target met ratio of 93.75% that have a potential upside of 32.11% achieved within 64 days.
Matthew Shea’s has documented 18 price targets and ratings displayed on 4 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TOI, Oncology Institute at 17-Jun-2026.
Analyst best performing recommendations are on PRVA (PRIVIA HEALTH GROUP).
The best stock recommendation documented was for TOI (ONCOLOGY INSTITUTE) at 3/9/2026. The price target of $5 was fulfilled within 91 days with a profit of $2.27 (83.15%) receiving and performance score of 9.14.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 17-Nov-2025
$6
$2.39 (66.20%)
$7
1 months 16 days ago
(18-Aug-2026)
0/2 (0%)
$1.42 (31.00%)
Buy Since 15-Nov-2016
$6
$2.54 (73.41%)
$5
1 months 17 days ago
(17-Aug-2026)
9/20 (45%)
$1.59 (36.05%)
1133
Hold Since 12-Aug-2026
$6
$2.54 (73.41%)
$7
1 months 22 days ago
(12-Aug-2026)
5/17 (29.41%)
$1.83 (43.88%)
87
Hold Since 11-Aug-2026
$6
$2.54 (73.41%)
$6.75
1 months 23 days ago
(11-Aug-2026)
1/7 (14.29%)
$1.9 (46.34%)
42
Buy Since 06-Jan-2016
$6
$2.54 (73.41%)
$7
1 months 24 days ago
(10-Aug-2026)
17/34 (50%)
$2.07 (52.67%)
467
Which stock is Matthew Shea most bullish on?
Which stock is Matthew Shea most reserved on?
What Year was the first public recommendation made by Matthew Shea?
